Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Nonalcoholic Fatty Liver DiseaseType 2 Diabetes Mellitus
Interventions
DRUG

Exenatide

The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.

Trial Locations (1)

78229-3900

The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of Florida

OTHER